A gene variant identified by scientists in California and Arizona nearly doubles the risk of a common type of blood cancer.
Researchers at the University of California, Berkeley (UC Berkeley) and at the Translational Genomics Research Institute (TGen) found that mutations in a gene called C6orf15, or STG, are linked to the risk of developing follicular lymphoma.
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess lymphoblasts. It is the most common of all childhood cancers and can be fatal in weeks if left untreated.
Advertisement
This is a cancer of the body's disease-fighting network whose rates have nearly doubled in the past three decades.
In the first genome-wide association study of non-Hodgkin lymphoma, scientists identified a SNP - a single nucleotide polymorphism - that could determine susceptibility to follicular lymphoma.
![Acute Myeloid Leukemia]( "Acute Myeloid Leukemia")
Acute myeloid Leukemia, more popularly known by its abbreviated form AML, is a fast- evolving leukemia that affects both children and adults alike
The SNP, a DNA variant within the more than 3-billion base pairs in the human genome, was identified as rs6457327.
The study was led by Dr. Christine Skibola, Associate Adjunct Professor of Environmental Health Sciences at UC Berkeley's School of Public Health, and by Dr. Kevin M. Brown, an Associate Investigator in the Integrated Cancer Genomics Division of TGen, a Phoenix-based, non-profit biomedical research institute.
"What's exciting about this study is that we found a target in the genome influencing the susceptibility to follicular lymphoma, which helps us discern between three major types of lymphomas," said Skibola.
"That had not been done before on a genome-wide scale. It is our hope that this research may some day be useful in helping develop prevention, early detection and treatment of this disease," Skibola added.
The researchers looked at variations in the gene and found that the presence of the G allele of SNP rs6457327 was actually protective against follicular lymphoma, occurring less frequently among people with the cancer.
In contrast, the presence of the A allele was predictive of an increased risk of developing follicular lymphoma. Brown said individuals who had the A allele were nearly twice as likely to develop follicular lymphoma.
"There's clearly a genetic component to the disease. The hope is to one day be able to take these results, combine them with other tests, and turn them into an individualized assessment of disease risk. This is a starting point," said Dr. Brown.
The genome-wide association study was conducted using DNA from a population-based non-Hodgkin lymphoma case-control study in the San Francisco Bay Area led by UC San Francisco researchers. Follow-up validation studies were done using independent case-control studies from Canada and Germany.
To reduce the potential for complicating factors, the more than 3,000 samples in the UC Berkeley-TGen study were from individuals who were HIV negative.
Dr. Brown said future studies could include HIV-positive individuals, if enough samples were made available.
The study has been published online by the science journal Nature Genetics.
Source: ANI
TAN
Acute Myeloid Leukemia
Acute myeloid Leukemia, more popularly known by its abbreviated form AML, is a fast- evolving leukemia that affects both children and adults alike
Advertisement
The SNP, a DNA variant within the more than 3-billion base pairs in the human genome, was identified as rs6457327.
The study was led by Dr. Christine Skibola, Associate Adjunct Professor of Environmental Health Sciences at UC Berkeley's School of Public Health, and by Dr. Kevin M. Brown, an Associate Investigator in the Integrated Cancer Genomics Division of TGen, a Phoenix-based, non-profit biomedical research institute.
"What's exciting about this study is that we found a target in the genome influencing the susceptibility to follicular lymphoma, which helps us discern between three major types of lymphomas," said Skibola.
"That had not been done before on a genome-wide scale. It is our hope that this research may some day be useful in helping develop prevention, early detection and treatment of this disease," Skibola added.
The researchers looked at variations in the gene and found that the presence of the G allele of SNP rs6457327 was actually protective against follicular lymphoma, occurring less frequently among people with the cancer.
In contrast, the presence of the A allele was predictive of an increased risk of developing follicular lymphoma. Brown said individuals who had the A allele were nearly twice as likely to develop follicular lymphoma.
"There's clearly a genetic component to the disease. The hope is to one day be able to take these results, combine them with other tests, and turn them into an individualized assessment of disease risk. This is a starting point," said Dr. Brown.
The genome-wide association study was conducted using DNA from a population-based non-Hodgkin lymphoma case-control study in the San Francisco Bay Area led by UC San Francisco researchers. Follow-up validation studies were done using independent case-control studies from Canada and Germany.
To reduce the potential for complicating factors, the more than 3,000 samples in the UC Berkeley-TGen study were from individuals who were HIV negative.
Dr. Brown said future studies could include HIV-positive individuals, if enough samples were made available.
The study has been published online by the science journal Nature Genetics.
Source: ANI
TAN
Potential Blood Cancer Therapy With an Arsenic-Based Agent
A team of experts led by researchers at Beth Israel Deaconess Medical Center (BIDMC) have found that an arsenic-based agent used in traditional Chinese medicine may help eliminate
Advertisement
 Scientists Discover Blood Cancer Cell Survival MechanismScientists have recently discovered what makes these white blood cells, called B lymphocytes or B cells, stay alive. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
